- Home
- CGEM vs BHRB Comparison
CGEM vs BHRB Comparison
Compare CGEM & BHRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGEM | BHRB |
|---|---|---|
| Founded | 2016 | 1852 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 968.8M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CGEM | BHRB |
|---|---|---|
| Price | $17.59 | $73.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $30.13 | ★ $71.80 |
| AVG Volume (30 Days) | ★ 510.9K | 116.8K |
| Earning Date | 05-11-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.46% |
| EPS Growth | N/A | ★ 173.76 |
| EPS | N/A | ★ 2.16 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $36.62 |
| Revenue Next Year | $5.20 | $10.06 |
| P/E Ratio | ★ N/A | $41.02 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $57.42 |
| 52 Week High | $19.43 | $75.09 |
Technical Indicators
Market Signals| Indicator | CGEM | BHRB |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 61.95 |
| Support Level | $17.19 | $61.32 |
| Resistance Level | $19.10 | N/A |
| Average True Range (ATR) | 0.89 | 1.60 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 81.78 | 79.88 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
About BHRB Burke & Herbert Financial Services Corp.
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.